← All organizations

Aimmune Therapeutics

For profitContributed to NMEWebsite ↗

Also known as: Aimmune Therapeutics | Aimmune Therapeutics, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Oct 31, 2025

Acquired by Nestle on Aug 31, 2020

Timeline

2010s

Jun 1, 2011
Aimmune Therapeutics— Founded

2020s

Jan 31, 2020
peanut allergen— NDA Organization
Jan 31, 2020
peanut allergen— NDA Secondary Org
Aug 31, 2020
Nestle— Acquired By

Drugs by trial phase (6 distinct, 13 trials)

Phase 3 (2 own, 0 via acquisition)

Phase 2 (3 own, 0 via acquisition)

Other trials (1 own, 0 via acquisition)

chia seed

Indications

Studied for

Marketed drugs (1)

peanut allergen

Recent trials (18)

NCT07218640Lead sponsorN/AOct 31, 2025
NCT04056299Study directorPhase 2Aug 31, 2019
NCT04056299Lead sponsorPhase 2Aug 31, 2019
NCT03736447Lead sponsorPhase 3Dec 27, 2018
NCT03736447Study directorPhase 3Dec 27, 2018
NCT03703791Lead sponsorPhase 3Oct 24, 2018
NCT03703791Study chairPhase 3Oct 24, 2018
NCT03682770CollaboratorPhase 2Oct 2, 2018
NCT03337542Lead sponsorPhase 3Oct 19, 2017
NCT03292484Lead sponsorPhase 3Oct 11, 2017
NCT03201003Lead sponsorPhase 3Jun 12, 2017
NCT03201003Study chairPhase 3Jun 12, 2017
NCT03126227Lead sponsorPhase 3May 8, 2017
NCT02993107Lead sponsorPhase 3Dec 1, 2016
NCT02635776Lead sponsorPhase 3Dec 1, 2015

Details

Founded: San Mateo, CA, US Jun 1, 2011
First NDA: Jan 31, 2020
Last known activity: Oct 31, 2025

Designations held

Fast track
Breakthrough therapy